Skip to content

XLenti™ Transient Production

Optimised third generation plasmids with enhanced safety profile and increased lentiviral yield, plus our GMP banked clonal suspension HEK293 cell line.

Plasmid Engineering

We custom-build plasmids containing your gene of interest and our proprietary XLenti™ expression system. Our custom engineering optimises transgene expression for small scale production and proof of concept studies.

Process Development

Our up- and downstream process development experts improve titre through process optimisation, then help expedite on-boarding of technologies and facilitate technology transfer.

Evaluate and License

Our optimised lentiviral packaging plamids outperform our competitors' in cell lines including our GMP banked, clonal suspension HEK293 cell line. The XLenti™ transient system is available to evaluate and license now.

Genetic medicine has experienced tremendous growth with the approval of multiple products that dramatically improve life. Lentiviral vectors are the key component for manufacturing many of these treatments. The free availability of lentiviral packaging plasmids will significantly reduce the time and cost to develop and commercialize these products.

Michael Chambers, CEO of Aldevron

Talk to the team about improving your lentiviral titre

Get in touch
Transient Lentiviral Production

XLenti™ 3rd generation, self-inactivating (SIN) lentivirus packaging plasmids have codon optimised promoter and packaging  sequences for increased translation efficiency, tightly controlled Tet inducible VSV-G and Gag-Pol expression to eliminate  its cytotoxic effect on cell growth, and low homology between expression cassettes for an improved safety profile.   Our plasmids, sold as p(ALD)Lenti are also available from our technology partner Aldevron.

OXGENE’s XLenti™ plasmid system outperforms all other commercially available  equivalents, including    in our GMP banked, serum-free,  clonal suspension HEK293 cell line. We  customise this system to optimise expression of any gene of interest, or for novel/non-standard  pseudotyping. 

Joining forces with OXGENE in the early stages of gene or cell therapy development allows our partners to establish and  optimise transient production, including validated production up to 10L scale, before transitioning to our stable packaging  and producer cell lines for large scale clinical manufacture. This provides the additional regulatory advantage of using the same genetic system throughout clinical development.

Have a look at our most recent poster here.

From our experts to yours: our scientists offer ongoing and detailed technical support, so you can have complete confidence in the performance of our technologies once transferred to your own facilities.

Get in touch with evaluation and licensing queries now.

Send us a message

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.

Login

Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of quality control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.